TABLE A5B.

Linear regression model to investigate whether trials with CDR‐SB as a primary endpoint have larger sample sizes than trials without, among Alzheimer's disease DMT clinical trials

	Sample size
Independent variables	Coefficient	P
Intercept	1210.540	.210
Has CDR‐SB	277.909 ***	.005
AD stage (reference = overt AD)
Presymptomatic	−961.732	.322
Prodromal/MCI	−996.694	.301
FDA registered trial	254.405 ***	.000
Phase (reference = phase III)
Phase II/III	−283.080 **	.039
Phase III/IV	−176.911 **	.010
DMT status	218.662 ***	.000
Number of observations	305
R‐squared	0.215

Abbreviations: AD, Alzheimer's disease; CDR‐SB, Clinical Dementia Rating; DMT, disease‐modifying therapy; FDA, Food and Drug Administration; MCI, mild cognitive impairment.

^** P < .05, ^***P < .01.